Tumor necrosis factor-alpha antagonists: Differential clinical effects by different biotechnological molecules

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 3, 2009, Pages 567-572

  Licastro, Federico ^a   Chiappelli, M ^a   Ianni, M ^a   Porcellini, E ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Autoimmune diseases; Differential clinical effects; TNF ; TNF inhibitors

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; SARCOIDOSIS; TREATMENT RESPONSE; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT; WEGENER GRANULOMATOSIS;

ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFLAMMATION; POLYETHYLENE GLYCOLS; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350549805     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200302     Document Type: Review

References (20)

1. Dinarello C. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147
2. Han C, Smolen JS, Kavanaugh A, et al. The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 2007; 9:103. (Pubitemid 350263514)
3. Klinkhoff A. Biological agents for rheumatoid arthritis: targeting both physical function and structural damage. Drugs 2004; 64:1267-1283 (Pubitemid 38916341)
4. Rigby WF. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior? Nat Clin Pract Rheumatol 2007; 3:227-233
5. Wong M, Ziring D, Korin Y, et al. TNF-alpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008; 126:121-136
6. Spencer-Green G. Etanercept (Enbrel): update on therapeutic use. Ann Rheum Dis 2000; 59: 46-49 (Pubitemid 30824959)
7. Senolt L, Vencovsky J, Pavelka K, Ospelt C, Gay S. Prospective new biological therapies for rheumatoid arthritis. Autoimmunity Rev 2009 doi 10.1016/jautrev.2009.03.010 in Pub Med.
8. Cliffon O, Bingham III O. Emerging therapeutics for rheumatoid arthritis. Bul NYU Hosp Joint Dis 2008; 66:210-215
9. Mitoma H, Horiuchi T, Hatta N, et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha. Gastroenterology 2005; 128:376-392 (Pubitemid 40431090)
10. Calabrese LH. Clinical management issues in vasculitis. Angiographically defined angiitis of the central nervous system: diagnostic and therapeutic dilemmas. Clin Exp Rheumatol 2003; 21:127-130
11. Schwartzman S, Morgan GJ Jr. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004; 6:19-23.
12. Mpofu S, Fatima F, Moots RJ. Anti-TNF-alpha therapies: they are all the same (aren't they?). Rheumatology 2005; 44:271-273 (Pubitemid 40361279)
13. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology 2007; 46:1153-1156 (Pubitemid 47050620)
14. Buch MH, Emery P. Non-response to tumor necrosis factor antagonists - is there any point in re-treatment? Nat Clin Pract Rheumatol 2006; 2:288-289
15. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, Quinn M, Emery P. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. Arthritis Rheum 2007; 57:448-453 (Pubitemid 46682532)
16. Di Poi E, Perin A, Morassi MP, Del Frate M, Ferraccioli GF, De Vita S. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. Clin Exp Rheumatol 2007; 25:85-87 (Pubitemid 46477490)
17. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56:13-20.
18. Erickson AR, Mikuls TR. Switching anti-TNF-alpha agents: what is the evidence? Curr Rheumatol Rep 2007; 9:416-420
19. Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. Rheumatol Int 2008; 28:553-559
20. Cohen G, Courvoisier N, Cohen JD, Zaltni S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. Clin Exp Rheumatol 2005; 23:795-800. (Pubitemid 43040507)